Astrana Health, Inc. (NASDAQ:ASTH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $65.17.

A number of research analysts recently weighed in on the company. BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Macquarie upgraded Astrana Health to a “hold” rating in a report on Monday, December 16th. Robert W. Baird upped their price target on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. TD Cowen assumed coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective for the company. Finally, KeyCorp initiated coverage on shares of Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock.

Astrana Health Stock Performance

Shares of ASTH stock opened at $29.48 on Friday. The company’s fifty day moving average price is $40.05 and its 200-day moving average price is $47.02. The stock has a market cap of $1.66 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 1.80 and a beta of 1.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 12 month low of $29.35 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same quarter in the previous year, the firm posted $0.47 earnings per share. On average, equities analysts expect that Astrana Health will post 1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASTH. State Street Corp bought a new stake in shares of Astrana Health during the 3rd quarter valued at about $91,966,000. Geode Capital Management LLC bought a new stake in Astrana Health during the third quarter valued at approximately $58,995,000. FMR LLC purchased a new stake in Astrana Health during the third quarter valued at approximately $48,413,000. SteelPeak Wealth LLC purchased a new stake in Astrana Health during the third quarter valued at approximately $39,398,000. Finally, Loomis Sayles & Co. L P bought a new position in Astrana Health in the third quarter worth approximately $30,251,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.